Charles River Acquires Two Frontage Labs for $470 Million

Charles River Laboratories is paying $470 million to acquire two Frontage bioanalysis laboratory sites in Pennsylvania.

The deal, which involves two facilities located in Exton, aims to expand the contract research organization’s footprint in the bioanalysis sector, Fierce Biotech reported. Frontage, a subsidiary of the Chinese clinical development provider Tigermed, could receive up to $75 million in additional payments depending on how the sites perform in the future, according to a Nov. 9 release.

Charles River is acquiring the company to expand its presence in the high-stakes drug development market. By absorbing these 150,000 square feet of laboratory space and the roughly 340 employees stationed there, the company is positioning itself to handle more complex biological testing.

“As biologics and increasingly complex modalities become a larger part of development pipelines, clients are seeking scientific partners that can support programs from early development through the clinic,” Charles River CEO Birgit Girshick said in the release.

Charles River Acquires Two Frontage Labs for $470 Million

The Exton sites specialize in a technical suite of services that are essential for bringing new drugs to market. This includes bioanalysis, biomarker testing, and drug metabolism and pharmacokinetics (DMPK) studies. These processes are critical for understanding how a drug interacts with the human body and whether it is safe and effective.

For pharmaceutical companies, the value of this acquisition lies in speed and continuity. When a single partner handles testing from the initial preclinical stages through to clinical trials, the risk of data gaps or delays decreases.

“Our combined bioanalysis and DMPK offering will provide a more integrated solution that accelerates development timelines and improves continuity from preclinical through clinical testing,” Birgit Girshick, Charles River CEO, said.

This acquisition is a direct implementation of the “pathway to purpose” strategy that Girshick introduced during the company’s 2026 investor day in September. That strategic vision focuses on reinforcing the company’s leadership in early-stage drug development by building out regulated testing capabilities across the entire research and development continuum.

The biotech industry is currently undergoing a massive shift. While traditional small-molecule drugs were once the standard, the industry is moving toward biologics—complex medicines derived from living organisms. These drugs are harder to manufacture and require much more sophisticated testing protocols to ensure stability and efficacy.

By securing these Pennsylvania labs, Charles River is betting that the demand for specialized testing will outpace the growth of simpler drug types. The move also consolidates expertise in the mid-Atlantic biotech corridor.

Tigermed, the parent company of Frontage, originally acquired Frontage in 2014 to build out its own global clinical trial network. While Tigermed remains a major player in clinical development services across China and the Asia-Pacific regions, this divestment of the Pennsylvania sites allows Charles River to absorb a specialized piece of that global infrastructure.

“This transaction is expected to enhance our growth profile and support long-term value creation for clients and shareholders,” Girshick said.